Cambridge Healthtech Institute’s 4th Annual

Immuno-Oncology Biomarkers

Predictive Biomarkers and Companion Diagnostics

August 5-6, 2019



As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s Fourth Annual Immuno-Oncology Biomarkers conference will bring together biomarkers experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.

LIQUID BIOPSY FOR IMMUNO-ONCOLOGY

Tumor-Derived Exosomes as Potential Biomarkers of Tumor Progression and Metastasis
Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine

Blood-Based Biomarkers of Response and Immune-Related Adverse Events During Immune Checkpoint Blockade
Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital

PREDICTIVE BIOMARKERS AND COMPANION DIAGNOSTICS FOR IMMUNO-ONCOLOGY

Predictive Biomarkers for Immunotherapy in Lung Cancer
Fred R. Hirsch, MD, PhD, Senior Faculty, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Image Mass Cytometry to Characterize the Tumor Immune Microenvironment
Maria Paola Serra, PhD, Senior Scientist, Pathology, AstraZeneca

Prognostic and Predictive Markers for Immunotherapy and Combination Therapy
Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute

GENOMIC BIOMARKERS IN IMMUNOTHERAPY DEVELOPMENT

Harnessing Immune Gene Signatures for Patient Prognosis and Discovery of Tumor Immune Evasion Tactics
Lance D. Miller, PhD, Associate Professor, Cancer Biology; Director, Breast Cancer Center of Excellence; Co-Director, Cancer Genomics Shared Resource, Wake Forest Baptist Comprehensive Cancer Center

The Cancer Genome's Influence on Immunotherapy
Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center

Assessing the Impact of Intratumoral Immune Modulation in Metastatic Melanoma
Cara Haymaker, PhD, Assistant Professor, Director, Oncology Research and Immuno-Monitoring Core (ORION), Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

BIOMARKERS TO GUIDE COMBINATION IMMUNOTHERAPY

TMB/GEP Dual Biomarker Strategy for Personalized Checkpoint Blockade Combination Immunotherapy
Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Possible Use of Immunoprofiling to Stratify or Direct Combination Immunotherapy
Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Providence Health & Services; CEO, UbiVac


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com